Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.
about
Role of complement and NK cells in antibody mediated rejectionPretransplantation erythropoiesis-stimulating agent hyporesponsiveness is associated with increased kidney allograft failure and mortality.Recent advances in renal transplantation: antibody-mediated rejection takes center stageRational clinical trial design for antibody mediated renal allograft injury.Immune Sensitization and Mortality in Wait-Listed Kidney Transplant Candidates.Ischemia-reperfusion injury accelerates human antibody-mediated transplant vasculopathyBanff 2011 Meeting report: new concepts in antibody-mediated rejectionIMPROVING LONG-TERM OUTCOMES IN KIDNEY TRANSPLANTATION: TOWARDS A NEW PARADIGM OF POST-TRANSPLANT CARE IN THE UNITED STATES.Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.Clinical role of the renal transplant biopsy.The impact of donor-specific anti-HLA antibodies on late kidney allograft failure.Phenotypes of antibody-mediated rejection in organ transplants.Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence.Histopathological diagnosis of acute and chronic rejection in pediatric kidney transplantation.The significance of histological diagnosis in renal allograft biopsies in 2014.The increasing clinical importance of alloantibodies in kidney transplantation.Chronic Antibody-Mediated Rejection in Nonhuman Primate Renal Allografts: Validation of Human Histological and Molecular Phenotypes.The over-exaggerated chronic nephrotoxicity of calcineurin inhibitorsThe Revised (2013) Banff Classification for Antibody-Mediated Rejection of Renal Allografts: Update, Difficulties, and Future Considerations.Current pathological perspectives on chronic rejection in renal allografts.Current status of pediatric renal transplant pathology.Postanastomotic transplant renal artery stenosis: association with de novo class II donor-specific antibodies.Clinical and pathological analyses of chronic vascular rejection after kidney transplantation.Renal allograft rejection: pieces of the puzzle.Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma.Kidney intragraft donor-specific antibodies as determinant of antibody-mediated lesions and poor graft outcome.Histopathological and clinical findings in renal transplants with Banff type II and III acute cellular rejection without tubulointerstitial infiltrates.The Role of the Endothelium during Antibody-Mediated Rejection: From Victim to Accomplice.Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association With Antibody-Mediated Rejection.Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation.Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.The Spectrum of Histopathological Changes in the Renal Allograft - a 12 Months Protocol Biopsy Study.
P2860
Q26864255-CB8DED8E-2AF9-4088-A3C6-71DCA07AFABFQ33871590-D1F6CFE3-663E-416A-B86D-F4B382562E5CQ35659332-F09C5FBB-0733-4545-88EB-2B3E2239F766Q36173541-9FD282EF-685A-4CE3-B642-BA6F9F9494A4Q36514884-752033D5-1B7D-46D5-9752-95999FFB4A88Q37044541-B1FE65EC-BB85-48CA-AB4B-B901C930ABCBQ37058043-781C4BD3-A332-46F3-BA4F-FC1096726BC1Q37563822-AAB3C9DB-DF3D-4E35-9213-AB56EAFA7DBAQ37660263-B18F8D93-41B5-4914-892C-5B04595F51F5Q37974480-FC7D69C1-C3D1-46B3-B0AE-16FCEEEE98DDQ38003049-AB949C41-B3BA-4116-A363-5B5AA94E2D3AQ38005448-38F7FA51-6CAA-4434-9904-AEDCF38A7082Q38116657-85699265-B731-441D-93A4-113EDA009B48Q38154130-F731CFCE-9C85-4778-B0C8-0401D0791D0FQ38247690-D2ACCE8B-B04B-41E4-B16F-53164186664DQ38258153-8A10085A-7EAC-491E-9A54-3C25DD7243A2Q38374793-6A9AC5BA-56FF-4CCE-94C0-011CF633BDFFQ38630386-C7794E52-AAA4-4BDE-9D6E-8122351FB273Q38676925-736B2178-0A24-4635-9A3F-71DB4D44E72FQ38795065-B9D5E1B5-3CE2-4BD1-95A8-22DB44BD9283Q38843499-9D5D25D6-F3EC-4570-BCEC-19C696182147Q40159121-9EB36BCD-C904-44A5-9D1F-A20BFE29E8A4Q40882057-314A15B5-7E41-498D-A48D-4DD45B76F56FQ42582852-F8CB1C7A-0736-49D6-A11B-E27027B8325FQ44911053-71EB6C79-0FC8-4682-BBBA-7AB465F0F807Q46322442-97DF229D-B519-42E4-B682-1CB5C9DAF41DQ48901557-CBBF5D49-0F34-4DF6-8645-2426D1324D83Q49521510-4B7B2333-53FB-4CDF-A3DA-F9C055F723F9Q50910367-58FAF10F-000C-4365-B247-020180C296EAQ52881666-9DAE9914-89BA-4500-86EC-C17FC6DF09CFQ52889823-F2737B77-3013-4B57-82A9-DBE048F792DAQ53825191-CD4E0FC2-031A-4F79-BAE8-C7D5D05E46F0
P2860
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.
@en
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.
@nl
type
label
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.
@en
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.
@nl
prefLabel
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.
@en
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.
@nl
P2093
P2860
P356
P1476
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation
@en
P2093
Alexandre Loupy
Caroline Suberbielle
Christophe Legendre
Dany Anglicheau
Dominique Nochy
Gary S Hill
J P Duong van Huyen
Jean-Philippe Empana
Patrick Bruneval
P2860
P304
P356
10.1681/ASN.2010070777
P577
2011-04-14T00:00:00Z